Document is current
Any future updates will be listed below
-
Authors
Carnero Contentti, Edgar http://orcid.org/0000-0001-7435-5726
Correale, Jorge
-
Funding
Funding for this research was provided by:
Guthy-Jackson Charitable Foundation (Not applicable)
- License Information
-
More Information
Article History
Received: 19 April 2021
Accepted: 24 August 2021
First Online: 16 September 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Edgar Carnero Contentti has received reimbursement for developing educational presentations, educational and research grants, consultation fees, and/or travel stipends from Biogen, Bayer, Genzyme, Merck, Novartis, Roche, Raffo, and Teva. ECC has also received grants from LACTRIMS and Guthy-Jackson Charitable Foundation. Jorge Correale is a board member of Merck-Serono Argentina, Novartis Argentina, Genzyme LATAM, Genzyme global, Biogen-Idec LATAM and Merck-Serono LATAM. He is part of the Steering Committee for the clinical trials of Ofatumumab (Novartis Global). JC has received reimbursement for developing educational presentations for Merck-Serono Argentina, Merck-Serono LATAM, Biogen-Idec Argentina, Genzyme Argentina, Novartis Argentina, Novartis LATAM, Novartis Global and Roche Argentina, as well as professional travel/accommodation stipends.
